Aging and osteoporosis in breast and prostate cancer

CA Cancer Journal for Clinicians

Volumn 61, Issue 3, 2011, Pages 139-156

  VanderWalde, Ari ^a,b   Hurria, Arti ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; COLECALCIFEROL; CYCLOPHOSPHAMIDE; DENOSUMAB; DEXAMETHASONE; DOXORUBICIN; ERGOCALCIFEROL; ESTROGEN; EXEMESTANE; GONADORELIN AGONIST; GOSERELIN; IBANDRONIC ACID; LETROZOLE; METHOTREXATE; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; TAMOXIFEN; TOREMIFENE; VITAMIN D; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; AGING; ANDROGEN DEPRIVATION THERAPY; BONE DENSITY; BREAST CANCER; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; EARLY MENOPAUSE; FRACTURE; FRAGILITY FRACTURE; HUMAN; JAW OSTEONECROSIS; NONHUMAN; ORCHIECTOMY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OSTEOSARCOMA; OVARIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SIDE EFFECT; WEIGHT BEARING; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; MALE; PROSTATE TUMOR;

AGING; ANTINEOPLASTIC AGENTS; BONE DENSITY; BREAST NEOPLASMS; FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 79959800630     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.20103     Document Type: Review

References (127)

1. Altekruse S, Kosary C, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute; .2010. Available at: http://seer.cancer.gov/csr/1975-2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010. Accessed December 16, 2010.
2. Khan MN, Khan AA. Cancer treatmentrelated bone loss: a review and synthesis of the literature. Curr Oncol. 2008; 15(Suppl 1):S30-S40.
3. Camacho PM, Dayal AS, Diaz JL, et al. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis. J Clin Oncol. 2008;26:5380-5385.
4. Nordin BE, Need AG, Steurer T, Morris HA, Chatterton BE, Horowitz M. Nutrition, osteoporosis, and aging. Ann N Y Acad Sci. 1998;854:336-351. (Pubitemid 29022814)
5. International Osteoporosis Foundation. Osteoporosis in the European Community: A Call to Action-An Audit of Policy Developments Since 1998. Lyon, France: International Osteoporosis Foundation; 2003.
6. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761-1767.
7. Jacobsen SJ, Goldberg J, Miles TP, Brody JA, Stiers W, Rimm AA. Race and sex differences in mortality following fracture of the hip. Am J Public Health. 1992;82: 1147-1149.
8. Guggenbuhl P. Osteoporosis in males and females: is there really a difference? Joint Bone Spine. 2009;76:595-601.
9. Dionyssiotis Y, Dontas IA, Economopoulos D, Lyritis GP. Rehabilitation after falls and fractures. J Musculoskelet Neuronal Interact. 2008;8:244-250.
10. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000;18:1570-1593. (Pubitemid 30205404)
11. Ecklund K, Laor T, Goorin AM, Connolly LP, Jaramillo D. Methotrexate osteopathy in patients with osteosarcoma. Radiology. 1997;202:543-547. (Pubitemid 27051757)
12. Glackin CA, Murray EJ, Murray SS. Doxorubicin inhibits differentiation and enhances expression of the helix-loop-helix genes Id and mTwi in mouse osteoblastic cells. Biochem Int. 1992;28:67-75.
13. Young DM, Fioravanti JL, Olson HM, Prieur DJ. Chemical and morphologic alterations of rabbit bone induced by adriamycin. Calcif Tissue Res. 1975;18:47-63.
14. Wang TM, Shih C. Study of histomorphometric changes of the mandibular condyles in neonatal and juvenile rats after administration of cyclophosphamide. Acta Anat (Basel). 1986;127:93-99. (Pubitemid 16031100)
15. Canalis E. Clinical review 83: mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab. 1996;81: 3441-3447. (Pubitemid 26339895)
16. Wasilewski-Masker K, Kaste SC, Hudson MM, Esiashvili N, Mattano LA, Meacham LR. Bone mineral density deficits in survivors of childhood cancer: long-term followup guidelines and review of the literature. Pediatrics. 2008;121:e705-e713.
17. Reid IR. Glucocorticoid osteoporosis-mechanisms and management. Eur J Endocrinol. 1997;137:209-217.
18. Ratcliffe MA, Lanham SA, Reid DM, Dawson AA. Bone mineral density (BMD) in patients with lymphoma: the effects of chemotherapy, intermittent corticosteroids and premature menopause. Hematol Oncol. 1992;10:181-187.
19. Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. Maturitas. 2009;65:161-166.
20. Gallagher JC. Effect of early menopause on bone mineral density and fractures. Menopause. 2007;14:567-571. (Pubitemid 46716174)
21. Saad F, Adachi JD, Brown JP, et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol. 2008;26: 5465-5476.
22. Teaff NL, Savoy-Moore RT, Subramanian MG, Ataya KM. Vinblastine reduces progesterone and prostaglandin E production by rat granulosa cells in vitro. Reprod Toxicol. 1990;4:209-213.
23. Berger CC, Bokemeyer C, Schuppert F, Schmoll HJ. Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer. 1996;73:1108-1114. (Pubitemid 26131233)
24. Brennemann W, Stoffel-Wagner B, Helmers A, Mezger J, Jager N, Klingmuller D. Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer. J Urol. 1997;158(3 pt 1):844-850.
25. Fogelman I, Blake GM, Blamey R, et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int. 2003;14:1001-1006. (Pubitemid 40824271)
26. Melton LJ, Crowson CS, Malkasian GD, O'Fallon WM. Fracture risk following bilateral oophorectomy. J Clin Epidemiol. 1996;49:1111-1115. (Pubitemid 26348607)
27. Melton LJ 3rd, Khosla S, Malkasian GD, Achenbach SJ, Oberg AL, Riggs BL. Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res. 2003; 18:900-905. (Pubitemid 37294974)
28. Antoniucci DM, Sellmeyer DE, Cauley JA, et al. Postmenopausal bilateral oophorectomy is not associated with increased fracture risk in older women. J Bone Miner Res. 2005;20:741-747. (Pubitemid 40571630)
29. Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev. 2008;34(suppl 1):S3-S18.
30. Kristensen B, Ejlertsen B, Dalgaard P, et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol. 1994;12:992-997. (Pubitemid 24145328)
31. Ward RL, Morgan G, Dalley D, Kelly PJ. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postemenopausal women. Bone Miner. 1993;22:87-94. (Pubitemid 23272793)
32. Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol. 2006;24:675-680. (Pubitemid 46630433)
33. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy xray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14:78-84. (Pubitemid 26022463)
34. Cooke AL, Metge C, Lix L, Prior HJ, Leslie WD. Tamoxifen use and osteoporotic fracture risk: a population-based analysis. J Clin Oncol. 2008;26:5227-5232.
35. Bell R, Lewis J. Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer. Curr Med Res Opin. 2007;23:1045-1051. (Pubitemid 46799586)
36. Goss PE, Qi S, Cheung AM, Hu H, Mendes M, Pritzker KP. Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res. 2004;10:5717-5723. (Pubitemid 39180947)
37. Goss PE, Hadji P, Subar M, Abreu P, Thomsen T, Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res. 2007;9:R52.
38. McCloskey EV, Hannon RA, Lakner G, et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer. 2007;41:2523-2531. (Pubitemid 350086940)
39. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008;26:1051-1057.
40. Forbes J, Cuzick J, Buzdar A, Howell A, Tobias J, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for earlystage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45-53.
41. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res. 2006;21:1215-1223. (Pubitemid 44128334)
42. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25:486-492. (Pubitemid 350002953)
43. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-1802. (Pubitemid 37362955)
44. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006; 24:3629-3635. (Pubitemid 46630537)
45. Geisler J, Lonning PE, Krag LE, et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebocontrolled study. Eur J Cancer. 2006;42: 2968-2975. (Pubitemid 44667475)
46. Lonning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005;23: 5126-5137. (Pubitemid 46224021)
47. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559-570.
48. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bonemineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007;8:119-127. (Pubitemid 46158372)
49. Hadji P, Ziller M, Kieback DG, et al. Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. Ann Oncol. 2009;20: 1203-1209.
50. Jones S, Stokoe C, Sborov M, et al. The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer. Clin Breast Cancer. 2008;8:527-532.
51. Mincey BA, Duh MS, Thomas SK, et al. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer. 2006;7:127-132. (Pubitemid 44044008)
52. Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab. 2009;94: 4785-4792.
53. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238-244. (Pubitemid 41043794)
54. Antonarakis ES, Blackford AL, Garrett-Mayer E, Eisenberger MA. Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. J Clin Oncol. 2007; 25:4998-5008. (Pubitemid 350220434)
55. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168: 1005-1007.
56. Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS. Low bone mineral density in hormone-na? ̈ve men with prostate carcinoma. Cancer. 2001;91:2238-2245. (Pubitemid 32552808)
57. Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K. Fracture risk in Danish men with prostate cancer: a nationwide register study. BJU Int. 2007; 100:749-754. (Pubitemid 47360203)
58. Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154-164. (Pubitemid 40096612)
59. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropinreleasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23:7897-7903. (Pubitemid 46657388)
60. Dickman PW, Adolfsson JAN, Astrom K, Steineck G. Hip fractures in men with prostate cancer treated with orchiectomy. J Urol. 2004;172:2208-2212. (Pubitemid 39507493)
61. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002;87:3656-3661. (Pubitemid 34879508)
62. Morote J, Orsola A, Abascal JM, et al. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol. 2006;175:1679-1683.
63. Miyaji Y, Saika T, Yamamoto Y, et al. Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Urology. 2004;64:128-131. (Pubitemid 38887592)
64. Preston D, Torrens J, Harding P, Howard R, Duncan W, McLeod D. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prostate Cancer Prostatic Dis. 2002;5: 304-310. (Pubitemid 36124442)
65. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000; 163:181-186.
66. Israeli R, Rosenberg S, Saltzstein D, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer. 2007;5:271-277. (Pubitemid 46867363)
67. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med. 2007;146:416-424. (Pubitemid 351650576)
68. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007;25:1038-1042. (Pubitemid 46596753)
69. Ryan CW, Huo D, Bylow K, et al. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int. 2007;100:70-75. (Pubitemid 46878544)
70. Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol. 2006; 176:972-978. (Pubitemid 44142571)
71. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169: 2008-2012. (Pubitemid 36576705)
72. Brufsky A, Bosserman L, Caradonna R, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST Study 36-month follow-up results. Clin Breast Cancer. 2009;9:77-85.
73. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25:829-836. (Pubitemid 350002883)
74. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer. 2008;112: 1001-1010. (Pubitemid 351304583)
75. Hines SL, Mincey B, Dentchev T, et al. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat. 2009;117:603-609.
76. Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD. Estrogendependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone. 2007;41:346-352. (Pubitemid 47199159)
77. Greenspan SL, Brufsky A, Lembersky BC, et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol. 2008;26:2644-2652.
78. Markopoulos C, Tzoracoleftherakis E, Polychronis A, et al. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res. 2010;12:R24.
79. Van Poznak C, Hannon R, Mackey JR, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol. 2010;28:967-975.
80. Lester JE, Dodwell D, Purohit OP, et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res. 2008;14: 6336-6342.
81. Layman R, Olson K, Van Poznak C. Bisphosphonates for breast cancer: questions answered, questions remaining. Hematol Oncol Clin North Am. 2007;21:341-367. (Pubitemid 46754735)
82. Mackey JR, Joy AA. Skeletal health in postmenopausal survivors of early breast cancer. Int J Cancer. 2005;114:1010-1015.
83. Body JJ, Bergmann P, Boonen S, et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer-a consensus paper of the Belgian Bone Club. Osteoporos Int. 2007;18:1439-1450. (Pubitemid 47512686)
84. McKean H, Looker S, Hartmann LC, et al. Are cancer survivors/patients knowledgeable about osteoporosis? Results from a survey of 285 chemotherapy-treated cancer patients and their companions. J Nutr Educ Behav. 2008;40:144-148. (Pubitemid 351615121)
85. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9: 1137-1141. (Pubitemid 24985932)
86. World Health Organization. WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level; Summary Meeting Report, Brussels, Belgium, 5-7 May 2004. Geneva, Switzerland: WHO Press; 2007.
87. U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann InternMed. 2002;137:526-528.
88. Qaseem A, Snow V, Shekelle P, et al. Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;148:680-684. (Pubitemid 351669113)
89. Nelson HD, Helfand M, Woolf SH, Allan JD. Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:529-541. (Pubitemid 35024625)
90. Nelson HD, Haney EM, Dana T, Bougatsos C, Chou R. Screening for osteoporosis: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2010;153: 99-111.
91. Felson DT, Zhang Y, Hannan MT, Anderson JJ. Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Miner Res. 1993;8:567-573. (Pubitemid 23127916)
92. Wardlaw GM. Putting body weight and osteoporosis into perspective. Am J Clin Nutr. 1996;63(3 suppl):433S-436S. (Pubitemid 26075826)
93. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A. Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteoporos Int. 2008;19:1395-1408.
94. World Health Organization Collaborating Centre for Metabolic Bone Diseases. FRAX v. 3.1. WHO Fracture Risk Assessment Tool. Available at: www.shef.ac.uk/FRAX/. Accessed July 27, 2010.
95. Murray TM. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 4. Calcium nutrition and osteoporosis. CMAJ. 1996;155:935-939.
96. Sanders KM, Nowson CA, Kotowicz MA, Briffa K, Devine A, Reid IR. Calcium and bone health: position statement for the Australian and New Zealand Bone and Mineral Society, Osteoporosis Australia and the Endocrine Society of Australia. Med J Aust. 2009;190:316-320.
97. Gralow JR, Biermann JS, Farooki A, et al. NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw. 2009;7(suppl 3):S1-S32; quiz S33-S35.
98. Gennari C. Calcium and vitamin D nutrition and bone disease of the elderly. Public Health Nutr. 2001;4:547-559. (Pubitemid 32524576)
99. Rodriguez-Martinez MA, Garcia-Cohen EC. Role of Ca(2\+) and vitamin D in the prevention and treatment of osteoporosis. Pharmacol Ther. 2002;93:37-49. (Pubitemid 34246440)
100. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years or older: a meta-analysis. Lancet. 2007;370:657-666. (Pubitemid 47285316)
101. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148:197-213. (Pubitemid 351665507)
102. Reid IR, Mason B, Horne A, et al. Randomized controlled trial of calcium in healthy older women. Am J Med. 2006;119: 777-785. (Pubitemid 44291631)
103. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293:2257-2264. (Pubitemid 40629192)
104. Nieves JW, Barrett-Connor E, Siris ES, Zion M, Barlas S, Chen YT. Calcium and vitamin D intake influence bone mass, but not short-term fracture risk, in Caucasian postmenopausal women from the National Osteoporosis Risk Assessment (NORA) study. Osteoporos Int. 2008;19:673-679.
105. Nogues X, Servitja S, Jesus Pena M, et al. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. Maturitas. 2010;66:291-297.
106. Hadji P, Body JJ, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol. 2008;19:1407-1416.
107. Bonaiuti D, Shea B, Iovine R, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 2002;(3):CD000333.
108. Kukuljan S, Nowson CA, Bass SL, et al. Effects of a multi-component exercise program and calcium-vitamin-D3-fortified milk on bone mineral density in older men: a randomised controlled trial. Osteoporos Int. 2009;20:1241-1251.
109. Nikander R, Sievanen H, Heinonen A, Daly RM, Uusi-Rasi K, Kannus P. Targeted exercise against osteoporosis: a systematic review and meta-analysis for optimising bone strength throughout life. BMC Med. 2010;8:47.
110. Drake MT, Cremers SC. Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition. Mol Interv. 2010;10:141-152.
111. Abrahamsen B. Bisphosphonate adverse effects, lessons from large databases. Curr Opin Rheumatol. 2010;22:404-409.
112. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362:1761-1771.
113. Holmberg L, Anderson H; HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363:453-455. (Pubitemid 38210063)
114. Kwan K, Ward C, Marsden J. Is there a role for hormone replacement therapy after breast cancer? J Br Menopause Soc. 2005;11:140-144. (Pubitemid 43103241)
115. von Schoultz E, Rutqvist LE; Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm Randomized Trial. J Natl Cancer Inst. 2005;97:533-535. (Pubitemid 40590435)
116. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49-57. (Pubitemid 34705518)
117. Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol. 2004; 171(6 pt 1):2272-2276. (Pubitemid 38625450)
118. Tyrrell CJ, Blake GM, Iversen P, Kaisary AV, Melezinek I. The non-steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World J Urol. 2003;21:37-42. (Pubitemid 44175295)
119. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010;8:162-200.
120. Higano C, Shields A, Wood N, Brown J, Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology. 2004;64:1182-1186. (Pubitemid 39647063)
121. Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology. 2001;57:127-132. (Pubitemid 32065833)
122. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropinreleasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89:3841-3846. (Pubitemid 39071482)
123. Smith MR, Malkowicz SB, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol. 2008;179:152-155. (Pubitemid 350216737)
124. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26:4875-4882.
125. Ellis GK, Bone HG, Chlebowski R, et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat. 2009;118:81-87.
126. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745-755.
127. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042-4057. (Pubitemid 46606220)